Menu Search
Equities

Selvita SA

787:FRA

Selvita SA

Actions
  • Price (EUR)15.36
  • Today's Change-0.16 / -1.03%
  • Shares traded100.00
  • 1 Year change-6.23%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.

  • Revenue in PLN (TTM)351.85m
  • Net income in PLN70.03m
  • Incorporated2019
  • Employees847.00
  • Location
    Selvita SAHexagon, Ul. Podole 79KRAKOW 30-394PolandPOL
  • Phone+48 123005001
  • Fax+48 122974701
  • Websitehttps://selvita.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SLV:WSE since
announced		Transaction
value
PozLab Sp z o oAnnounced27 Mar 202427 Mar 2024Announced9.48%6.29m
Data delayed at least 15 minutes, as of Apr 26 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.